Cargando…
A Novel BRD Family PROTAC Inhibitor dBET1 Exerts Great Anti-Cancer Effects by Targeting c-MYC in Acute Myeloid Leukemia Cells
Acute myeloid leukemia (AML) represents an aggressive hematopoietic malignancy with a prognosis inferior to that of other leukemias. Recent targeted therapies offer new opportunities to achieve better treatment outcomes. However, due to the complex heterogeneity of AML, its prognosis remains dismal....
Autores principales: | Zhang, Kunlong, Gao, Li, Wang, Jianwei, Chu, Xinran, Zhang, Zimu, Zhang, Yongping, Fang, Fang, Tao, Yanfang, Li, Xiaolu, Tian, Yuanyuan, Li, Zhiheng, Sang, Xu, Ma, Li, Lu, Lihui, Chen, Yanling, Yu, Juanjuan, Zhuo, Ran, Wu, Shuiyan, Pan, Jian, Hu, Shaoyan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272305/ https://www.ncbi.nlm.nih.gov/pubmed/35832114 http://dx.doi.org/10.3389/pore.2022.1610447 |
Ejemplares similares
-
BRD4 PROTAC degrader MZ1 exerts anticancer effects in acute myeloid leukemia by targeting c-Myc and ANP32B genes
por: Ma, Li, et al.
Publicado: (2022) -
BRD4 PROTAC degrader ARV-825 inhibits T-cell acute lymphoblastic leukemia by targeting 'Undruggable' Myc-pathway genes
por: Wu, Shuiyan, et al.
Publicado: (2021) -
BRD4 Inhibitor GNE-987 Exerts Anticancer Effects by Targeting Super-Enhancer-Related Gene LYL1 in Acute Myeloid Leukemia
por: Sang, Xu, et al.
Publicado: (2022) -
The BRD4 Inhibitor dBET57 Exerts Anticancer Effects by Targeting Superenhancer-Related Genes in Neuroblastoma
por: Jia, Si-Qi, et al.
Publicado: (2022) -
The BET PROTAC inhibitor dBET6 protects against retinal degeneration and inhibits the cGAS-STING in response to light damage
por: Zhu, Xingfei, et al.
Publicado: (2023)